A single-center retrospective study from MD Anderson in patients with core binding factor CBF AML shows that FLAG-GO gives a survival advantage over FLAG-IDA (p = 0.04), which is more pronounced in patients younger than 60 years. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.